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REVIEW ARTICLE OPEN
Interventions to improve medication adherence in tuberculosis
patients: a systematic review of randomized controlled studies
Ivan S. Pradipta 1,2,3✉, Daphne Houtsma1, Job F. M. van Boven4,5, Jan-Willem C. Alffenaar4,6,7,8 and Eelko Hak1,5
Non-adherence to anti-tuberculosis (anti-TB) medication is a major risk factor for poor treatment outcomes. We therefore assessed
the effectiveness of medication adherence enhancing interventions in TB patients. We report a systematic review of randomized
controlled trials that included either latent tuberculosis infection (LTBI) or active TB patients. Outcomes of interest included
adherence rate, completed treatment, defaulted treatment and treatment outcomes. We identified four LTBI and ten active TB
studies. In active TB patients, directly observed treatment (DOT) by trained community workers, short messaging service combined
with education, counselling, monthly TB vouchers, drug box reminders and combinations of those were found effective. In LTBI
patients, shorter regimens and DOT effectively improved treatment completion. Interestingly, DOT showed variable effectiveness,
highlighting that implementation, population and setting may play important roles. Since non-adherence factors are patient-
specific, personalized interventions are required to enhance the impact of a programme to improve medication adherence in TB
patients.
npj Primary Care Respiratory Medicine           (2020) 30:21 ; https://doi.org/10.1038/s41533-020-0179-x
INTRODUCTION
Tuberculosis (TB) remains an important worldwide health issue.
World Health Organization (WHO) reported that TB is the cause
of illness for around 10 million people every year and has been
ranked among the top ten causes of death globally1. TB, caused
by Mycobacterium tuberculosis, can be spread easily from
patients suffering from pulmonary TB to healthy people by air
transmission1. Consequently, anti-TB drug treatment is required
for TB patients to cure the disease and prevent disease
transmission.
Comparable to other complex diseases, TB patients have to be
treated with several drugs for a long period. According to the
WHO guideline, active pulmonary TB patients should take drugs
for at least 6 months2, while latent tuberculosis infection (LTBI)
patients should take drugs for at least 3 months3. The treatment
duration can be extended if TB patients are diagnosed as multi-
drug resistant tuberculosis (MDR-TB), a resistance of the
pathogen to the most potent anti-TB medicines (isoniazid and
rifampicin). MDR-TB treatment can be up to 24 months using
multiple drugs4.
Poor adherence to medication is widely known as a causal
factor for increased risk of morbidity, mortality and cost burden5–7.
A global meta-analysis revealed that non-adherence to treatment
is a risk factor for MDR-TB8. Furthermore, MDR-TB patients, as
compared to drug-susceptible patients, have more frequently
poor treatment outcomes9,10. Treatment adherence is affected by
multiple factors. These factors are divided into five different
interacting dimensions, including socio-economic, health care
system, condition, therapy and patient factors11. Although studies
on adherence in other diseases than TB showed that interventions
targeting these factors can significantly improve adherence
rates12–14, a better understanding of the effects of possible
interventions in TB is required. We therefore systematically
reviewed the effectiveness of various interventions to improve
medication adherence in LTBI and active TB patients.
RESULTS
Study selection
During the search, we found 200 records from the Medline/
PubMed database and 186 records from the Cochrane database.
We identified 72 duplicate records using the Refwork® software. A
total of 314 articles were screened for the title and abstract. This
initial screening excluded 268 irrelevant records, then the full-text
screening process was continued for 46 records. In the full-text
screening, 32 articles were excluded owing to different popula-
tions (3 articles), different study outcomes (12 articles) and non-
randomized study design (17 articles). We finally analysed
14 studies for qualitative synthesis. The flow diagram, literature
search and screening process are presented in Fig. 1.
Study characteristics and interventions
In total, 15,507 subjects were included in the analysis. In all, 1991
LTBI patients and 13,516 active TB patients participated. The
minimum number of subjects in the included studies was 89,
while the maximum number was 4154 subjects. The included
studies were conducted in both low- and high-burden TB
countries, i.e. Pakistan15,16, Australia17, Iraq18, China19,20, Senegal21,
South Africa22–24, Timor Leste25, Canada26, United States24,27,
Spain24, Hong Kong24 and Mexico28.
The 14 randomized controlled trials (RCTs) assessed a broad
range of adherence management interventions. These included
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Short Message Service (SMS) intervention15,16,18–20,24, directly
observed treatment (DOT) administered by health care workers24,
family members17 and non-health care worker communities18,22, a
reinforced counselling method21, a trained lay health workers
intervention to manage TB case22, monthly TB vouchers23, a drug
box reminder20, a combination text messaging and drug box
reminder20, a nutritious intervention25, shorter regimen26, a peer-
based intervention27 and a behavioural intervention28. The
characteristics of the included studies are shown in Table 1.
Study outcomes
In the active TB patients, the primary outcomes were treatment
completion15–17,19,22,23, interrupted rate15,16,18,21,23 and adherence
rate20,25, while the other outcomes were negative sputum
conversion18,19, cured18,21 and poor treatment outcomes20. In
the LTBI studies, we observed that treatment completion was the
only outcome. Regarding the intervention effect, not all interven-
tions significantly improved drug adherence and treatment
outcomes. Several interventions were found effective in improving
medication adherence and outcomes of active TB patients, i.e.
DOT by trained community members, SMS combined with TB
education, a reinforced counselling method, monthly TB voucher,
drug box reminder and a combination drug box reminder and text
messaging. However, only two studies reported adherence rate as
the study outcome20,25. We identified that a drug box reminder
(mean ratio (MR) 0.58; 95% confidence interval (CI) 0.42 to 0.79)
and its combination with text messaging (MR 0.49; 95% CI 0.27 to
0.88) significantly reduced missing a drug dose among active TB
patients20, while food incentives were not significantly different
from the comparator for the intensive (MR −4.7; 95% CI −0.8
to −8.6) and continuation phase (MR 0; 95%CI −1.7 to 1.7) in the
active TB patients25, see Table 2.
In the LTBI patients, shorter regimens and DOT interventions
significantly improved treatment completion. We identified that
4 months of daily rifampicin 10 mg/kg was more effective to
improve treatment completion than 9 months of daily isoniazid
5 mg/kg (relative risk (RR) 1.2; 95% CI 1.02–1.4)26, while DOT
intervention was more effective to improve treatment completion
than self-administration therapy (SAT) with monthly monitoring
(RR 1.18; 95% CI 1.09–1.27)24. In contrast, several interventions
such as SAT with weekly text message reminders plus monthly
monitoring (RR 1.03; 95% CI 0.95–1.13)24, a peer-based interven-
tion (RR 1.06; 95% CI 0.86–1.31)27, adherence coaching interven-
tion (RR 1.36; 95% CI 0.98–1.88)28 and self-esteem counselling (RR
1.12; 95% CI 0.78–1.58)28 did not significantly improve treatment
completion in LTBI patients, see Table 3.
Quality assessment of the included studies
A double-blinding method was either not possible or not applied
for most of the included studies. This is due to the fact that
intervention activities were impossible to blind, such as SMS
reminders, DOT, counselling, monthly vouchers, drug box
reminders, food incentive and peer-based intervention. Often, an
open-label design was applied. Therefore, none of the included
had a maximum JADAD score (five points). Three points of the
JADAD score was the maximum score among the included studies
because none of the studies applied the blinding method. Five of
the 14 studies had the lowest JADAD score (2 points) due to the
absence of a description of randomization procedure17–19,27,28.
The other studies had a higher score (three points) given they
appropriately described the randomization method and clearly
200 records identified through 
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32 full-text articles excluded: 
• Different population (3) 
• Different outcome (12) 
• Non-randomized studies: (17) 
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Fig. 1 Flow diagram of the included articles. The PRISMA flowchart reporting the number of papers identified, screened, excluded and
included.
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illustrated the withdrawals of participants15,16,20–26. The risk of bias
assessment is presented in Table 4.
DISCUSSION
We observed various interventions that were successful in
improving medication adherence and outcomes in TB patients.
The interventions targeted several factors of adherence, such as
socio-economic, patient, health care and treatment aspects. The
effective interventions to improve treatment completion in active
TB patients were DOT with daily home visits by community-
trained members, SMS reminders combined with TB education, a
reinforced counselling method and a monthly voucher interven-
tion. In LTBI patients, DOT and a shorter regimen significantly
improved treatment completion. We identified that the drug box
reminder or its combination with text messaging reminders
significantly improved medication adherence rates among active
TB patients, while no studies were found showing an effective
intervention to improve medication adherence rate in LTBI
patients. In contrast, we found that some interventions, such as
SMS reminders or its combination with motivational messages,
family DOT, involving trained lay health workers in TB manage-
ment, and food incentives were not significantly different
compared with the comparator groups regarding improving
treatment completion and outcomes in active TB patients.
Similarly, we identified SMS reminders combined with monthly
monitoring, peer-based intervention, coaching adherence and
self-esteem counselling were not effective in improving treatment
completion in LTBI patients.
Interestingly, interventions using DOT showed variable effects
on the study outcomes. Family DOT17 were not superior in the
improvement of treatment outcomes among active TB patients,
while institutional DOT significantly improved treatment comple-
tion in LTBI patients. Unfortunately, a meta-analysis of the crude
data was impossible, because heterogeneities were identified
across the included studies with regard to population, interven-
tion and study outcomes. However, a previous meta-analysis
stated that the understanding of resources and situations in which
DOT can be beneficial is an essential part of successful
implementation of DOT29. Furthermore, the interaction between
DOT providers and TB patients may also influence the effect on
medication adherence and outcome. Therefore, the differences of
resources, situation and interaction between DOT providers and
TB patients may indicate that the effects of interventions can vary
across studies and settings.
Generally, the differences in observed effect sizes of the
interventions in this review can be explained by several aspects: (1)
characteristics of the subjects, (2) measurement method of the
adherence (outcome), (3) characteristics of the comparator group,
and (4) the quality of the study design and intervention. According to
WHO11, adherence is a multidimensional phenomenon that can be
determined by the interaction of the five essential factors, i.e., socio-
economic, provider–patient/health care system, condition related,
therapy related and patient related. Since the essential causal factors
for poor adherence can be individual, assessing the individual non-
adherence factors is a critical approach to have effective personalized
interventions to increase medication adherence. The most optimal
intervention to improve medication adherence should not be “one-
size-fits-all”. As an example, an intervention using SMS reminders for
taking medicine may not be effective if the individual problem of
medication adherence is mainly caused by inaccessibility of the
patient to have a qualified medicine.
In terms of outcome measurement, heterogeneity was shown in
the included studies. Most of the studies used a treatment
completion parameter measured by temporary patient visits or
self-reported/medical documentation as the outcome parameter
for medication adherence. An implication of this is the possibility
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did not represent the daily consumption of the medicines during
the treatment phase. Hence, potential information bias is high in
the studies that used temporary patient visits or self-reported/
medical documentation to assess medication adherence. The
accuracy of adherence measurement in TB patients was reported
in a systematic review30. Methods to measure adherence can be
categorized as direct (e.g. DOT, ingestible sensors, drug or
metabolites measurements) and indirect (e.g. patient self-report,
pill counts, health information system, electronic pill bottles and
SMS). Currently, digital adherence technologies have been
developed that offer large potential to measure and improve
medication adherence in TB patients31. The technology potentially
facilitates monitoring of adherence that provides a more patient-
centric approach than the existing DOT32. The digital technology
for monitoring medication adherence of TB patients was reported
in the form of video observed therapy and electronic medication
monitoring33. Measurement of medication adherence was also
reported using pharmaceutical databases33. However, considering
the accuracy and validity, direct measurement should be
preferably used for measuring medication adherence in an
interventional study.
There were some variations in the comparator group in the
included studies, which may also have affected the validity of the
findings. We noted that self-administration of treatment without
supervision and DOT were the comparator groups in the included
studies. Theoretically, the effect of the studied intervention will be
higher in the studies that used self-administration without
supervision as the comparator group instead of DOT. A previous
study showed that DOT was more effective than SAT in the
improvement of treatment adherence34 and DOT was also
recommended by WHO for improving treatment adherence in
TB patients34. It is possible, therefore, that using different
comparators to compare two or more intervention studies will
lead to an under- or over-estimation.
Another aspect, which may explain the variations in the results
of studied interventions, is the quality of the included studies.
Among the randomized studies, the randomization method was
unclear in five studies17–19,27,28. The investigators did not describe
how the random allocation was conducted. In most of the
included studies, blinding was impossible. Since the intervention
involved direct activities with the research subjects such as
reminders, counselling, education and incentives, performing a
blinding procedure was impossible. In addition, the quality of
implementation of the intervention is also essential. For instance,
in DOT studies, the ability of the treatment observer to improve
medication adherence of TB patients will affect the success of the
intervention. As previously described, the interaction between
treatment observer and TB patients should therefore be
considered in order to understand potential changes in medica-
tion adherence.
Several limitations to our review should be acknowledged. First,
the review was based on the two databases with restriction to
English publications and searching period, hence not all the
intervention studies may be covered in this study. However, to the
best of our knowledge, the vast majority of relevant studies are
published in the English language and recent trials incorporated
knowledge from the potential trials before 2003. Second, only a
few studies used adherence rate as the study outcome. Most of
the studies mentioned treatment outcomes (i.e. sputum conver-
sion, cured and poor treatment outcome) but did not include
sufficient detail on medication adherence as the study outcome.
Since treatment outcomes were associated with medication
adherence in previous studies5,6,8, we included treatment out-
comes as the secondary outcomes in this review. Therefore, the
effectiveness of the interventions to improve medication adher-
ence, as reported in the studies, should be carefully interpreted,
and clearly high-quality intervention studies should be developed
in the future. Lastly, in order to assess intervention effects in a
homogeneous population regarding patient characteristics, this
review excluded interventions in more complex or high-risk TB
patients, such as those with comorbid human immunodeficiency
virus (HIV), drug-resistant TB, alcoholism and illicit drug use. We
acknowledge that these are, however, important subgroups
regarding non-adherence, for which we recommend separate,
focussed studies and reviews.
Table 4. Risk of bias assessment for randomized studies using the JADAD score.












1 1 0 0 1 3
2 MacIntyre et al.17 1 0 0 0 1 2
3 Mohan et al.18 1 0 0 0 1 2
4 Belknap et al.24 1 1 0 0 1 3
5 Fang et al.19 1 0 0 0 1 2
6 Hirsch-Moverman
et al.27
1 0 0 0 1 2
7 Thiam et al.21 1 1 0 0 1 3
8 Clarke et al.22 1 1 0 0 1 3
9 Farooqi et al.16 1 1 0 0 1 3
10 Hovell et al.28 1 0 0 0 1 2
11 Lutge et al.23 1 1 0 0 1 3
12 Menzies et al.26 1 1 0 0 1 3
13 Liu et al.20 1 1 0 0 1 3
14 Martins et al.25 1 1 0 0 1 3
The JADAD questions: (1) Was the study described as randomized?; (2) Was the method used to generate sequence of randomization described and
appropriate?; (3) Was the study described as double blind?; (4) Was the method of double-blinding described and appropriate?; (5) Was there a description of
withdrawals and dropouts? A double-blinding method was either not possible or not applied for the included studies.
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Our review highlighted various potential interventions to
improve medication adherence among LTBI and active TB
patients. Characteristics of the research subjects, accurate
measurement of the adherence, type of the comparator group,
the robustness of study design and implementation of the
intervention should be considered to observe an effective and
unbiased intervention for medication adherence in TB patients.
Since non-adherence factors can be individual, interventions that
takes into account individual patient barriers are required to have
an effective medication adherence programme. Therefore, future
intervention studies should use objective adherence measures
and focus on the effectiveness of TB medication adherence
programmes that use a more personalized approach.
METHODS
Literature review
We performed a systematic review of articles that were published
between January 1, 2003 and April 24, 2018 and reported in the
English language. According to the study protocol, the search
period was restricted to articles published from 2003 onwards
because in that year the influential WHO Adherence report was
published and created wide-scale awareness on the issue of non-
adherence ever since11. This systematic review was reported
according to Preferred Reporting Items for Systematic Reviews
and Meta-Analyses guidance35. The PICOS items, i.e. population,
intervention, comparator, outcomes and study design, are
specified in the following sections.
Population
To be able to better distinguish between the potential impact of
experienced symptoms on extent of adherence, the study
population was divided into two different groups, i.e. patients
with LTBI and active TB. The status of TB disease should be
confirmed by clinical or laboratory examination (e.g. TB symptoms,
Mantoux, IGRA, chest radiograph or other TB examination) and/or
microbiological verification (e.g. smear sputum test, phenotyping
drug susceptibility test or polymerase chain reaction). In order to
draw conclusions based on a population as homogeneous as
possible, we excluded studies restricted to specific high-risk
treatment non-adherence groups, such as TB patients with HIV,
drug-resistant TB, alcoholism and illicit drug use.
Interventions and comparator
Studies that analysed interventions related to improving medica-
tion adherence and treatment outcomes were included in this
review. The intervention was allowed to target one or multiple
factors of adherence, such as socio-economic, health care team
and system, health condition, therapy or patient factors. The
intervention should have a comparison group to analyse the effect
of the intervention.
Outcomes
In terms of the study outcomes, we followed the global definition
published by WHO in 201436. We defined medication adherence
as the primary outcome. Of note, medication adherence consists
of three phases: initiation, implementation, and persistence37. In
our assessment, persistence was deemed a synonym for
“completed treatment” and non-persistence was a synonym for
“defaulted treatment”. Implementation was deemed similar to
“adherence rate”. Moreover, we defined “cured treatment”,
“negative sputum conversion” and “poor treatment” outcomes
as the secondary outcome in this study.
According to the global definition, “completed treatment” was
defined as a TB patient who completed treatment without
evidence of failure but with no record showing that sputum
smear or culture results were positive in the last month of
treatment, while “defaulted treatment” was defined as an
interruption of TB treatment for two or more consecutive months.
“Adherence rate” was identified by the proportion of anti-TB drug
dose taken during the treatment period. As the other outcomes,
“cured treatment” was defined as smear or culture negative in the
last month of treatment and on at least one previous occasion,
while “negative sputum conversion” was defined as the conver-
sion sputum to a negative result. Furthermore, “poor treatment
outcome” is a combination of defaulted, failed treatment and
death outcome. Failed treatment was defined as a positive
sputum smear or culture at the fifth month after treatment
initiation.
Study design
We only included RCTs. Given their increased risk for bias, quasi-
experimental, cohort, cross-sectional, case–control, case reports,
case series, review articles and abstract conference were not
eligible for inclusion.
Data collection
The relevant articles were obtained from the Medline/PubMed
and Cochrane databases with specific key terms. To effectively
obtain the relevant articles, we used restriction to the following
filters in the Medline/PubMed database, such as clinical trial,
comparative study, controlled clinical trial, observational study,
RCT and humans. Applying observational study in the Medline/
PubMed filter was intended to anticipate potential RCTs in the
group labelled as observational studies. Key terms for obtaining
the articles can be found in Supplementary Information.
Data extraction and quality assessment
Title and abstract of the articles were screened by I.S.P. and D.H.,
then the full-text of the articles were assessed for the eligibility
and quality by I.S.P. Duplicated articles from two databases were
removed using the Refwork® software. The eligible articles were
then reviewed for relevant information. Information related to
year of publication, population, type of intervention, comparator
group and study outcome was extracted by I.S.P. Any disagree-
ments between the reviewers during the screening phase were
solved by discussion until consensus was reached.
Regarding the quality assessment, we used the JADAD score for
assessing the quality of the RCTs38. Three main domains were
appraised in the JADAD score system, i.e. randomization, blinding
method and subject withdrawal. The domains were assessed by five
questions. For each question, a study could earn one point, with a
total score of five points. The five questions are described as follows:
Was the study described as randomized?; Was the method used to
generate sequence of randomization described and appropriate?;
Was the study described as double blind?; Was the method of
double-blinding appropriately described?; and Was there a descrip-
tion of withdrawals and dropouts?
Summary measures and synthesis of results
The total number and group of patients with any specific outcome
for both primary and secondary outcomes were extracted by I.S.P.
and summarized in tables. For the point estimate of the
intervention, we used RR for dichotomous outcome data and
MR for continuous outcome data with a 95% CI.
Reporting summary
Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
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